STOCK TITAN

Ionis (IONS) Rule 144 Notice — 28,000 Shares via UBS on NASDAQ

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Notice of proposed sale under Rule 144: The filing reports the proposed sale of 28,000 common shares, acquired the same day by exercise of stock options and paid in cash. The broker named is UBS Financial Services, Inc. (11 Madison Avenue, New York). The aggregate market value of the shares is listed as $1,680,000.00, with 159,391,229 shares outstanding and an approximate sale date of 09/03/2024 on NASDAQ. The filer reports no securities sold in the past three months and includes the standard signature representation re: material nonpublic information and Rule 10b5-1 plan language.

Positive

  • Full disclosure of transaction mechanics: acquisition date, nature (option exercise), payment method, broker, and planned sale date are provided
  • No reported sales in prior three months, suggesting this may be a one-off disposition rather than ongoing insider selling

Negative

  • Issuer and filer identity fields are incomplete in the form content, limiting context about the specific insider or corporate role
  • No detail on whether a Rule 10b5-1 plan applies beyond the generic representation, so the filing does not clarify pre-arranged trading instructions

Insights

TL;DR: Insider exercised options and intends to sell 28,000 shares via UBS on NASDAQ, representing a routine Rule 144 notice.

The filing documents a same-day option exercise and proposed sale of 28,000 common shares with an aggregate market value of $1.68M. The transaction is routed through a major broker and scheduled for 09/03/2024. No prior sales in the past three months are reported, which may indicate this is an isolated disposition rather than part of a recurring selling pattern. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.

TL;DR: This is a standard Rule 144 notice documenting an option exercise and planned market sale; disclosures appear routine.

The notice provides necessary mechanics: acquisition date, nature of acquisition (stock option exercise), payment in cash, broker details, and outstanding share count. The absence of reported sales in the prior three months and the inclusion of the signature representation align with typical compliance practices. No governance concerns or material adverse events are disclosed in this filing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does this Form 144 for IONS report?

It reports a proposed sale of 28,000 common shares acquired by exercise of stock options and paid in cash, with an aggregate market value of $1.68M.

When is the approximate date of sale listed on the Form 144?

The approximate sale date is listed as 09/03/2024.

Through which broker will the shares be sold?

The broker named is UBS Financial Services, Inc. at 11 Madison Avenue, New York, NY.

Does the filing report any securities sold by the same person in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

How many shares outstanding does the filing list?

The filing lists 159,391,229 shares outstanding.
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

12.95B
160.75M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD